New hope for rare amyloidosis: targeted drug combo enters trial

NCT ID NCT07224672

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase 2 trial tests a new drug, belantamab mafodotin, combined with standard chemotherapy in 60 adults newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. The goal is to see if the combination improves blood and organ responses. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (a targeted antibody) combined with cyclophosphamide, bortezomib, and dexamethasone (chemotherapy drugs)
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with newly diagnosed AL amyloidosis, potentially improving organ function and survival.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 60 participants. The drug combination may cause side effects, including eye problems, and may not prove more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOIDOSIS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Rochester, Minnesota, 55905, United States
GSK Investigational Site
RECRUITING

Westmead, New South Wales, 2145, Australia
GSK Investigational Site
RECRUITING

Woolloongabba, Queensland, 4102, Australia
GSK Investigational Site
RECRUITING

Box Hill, Victoria, 3128, Australia
GSK Investigational Site
RECRUITING

Frankston, Victoria, 3199, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.